In addition, CCR2 inhibitor treatment has been reported to enhance anti-tumor immunity in PDAC [184], and has shown tolerability in PDAC patients [185], possibly also having inhibitory effects on neural invasion or tumor innervation. This evidence concerns the gene CCR2 and neoplasm.